4 terminated, 3 recruiting, 3 unknown, 2 completed. 8 Phase 1, 5 Early Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 4, Recruiting 3, Completed 1 |
| Early Phase 1 | 5 | Unknown 3, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Recruiting 3 |
Follow Eureka Therapeutics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion - Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL) | Early Phase 1 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 3 | 2025-12-31 | 2025-09-17 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma ET140203 T Cells - Hepatoblastoma, Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Recruiting | Eureka Therapeutics Inc. | 12 | 2022-07-19 | 2026-07-06 |
| GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC ECT204 T cells - Hepatocellular Carcinoma, Liver Cancer, Adult | Phase 1 / Phase 2 | Recruiting | Eureka Therapeutics Inc. | 60 | 2022-03-11 | 2026-09-10 |
| Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) ET140203 autologous T cell product - Hepatocellular Carcinoma, Liver Cancer | Phase 1 | Terminated | Eureka Therapeutics Inc. | 8 | 2021-04-14 | 2025-09-08 |
| Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma ET140202 autologous T cell product - Hepatocellular Carcinoma, Liver Cancer | Phase 1 | Terminated | Eureka Therapeutics Inc. | 2 | 2019-05-30 | 2022-08-23 |
| ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer Sorafenib combined with ET140202-T cell, TAE combined with ET140202-T cell, ET140202-T cell - Hepatocellular Carcinoma, Liver Cancer | Early Phase 1 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 27 | 2019-05-30 | 2019-08-08 |
| Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies Low dose ET019002- T Cells, Middle dose ET019002- T Cells, High dose ET019002- T Cells - B-Cell Malignancies | Early Phase 1 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 18 | 2018-08-19 | 2018-08-23 |
| Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma ET190L1 ARTEMIS™ T cells - Lymphomas Non-Hodgkin's B-Cell | Phase 1 | Terminated | Eureka Therapeutics Inc. | 4 | 2018-04-04 | 2019-02-04 |
| ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma ET190L1-ARTEMIS™ T cells -iv low dose, ET190L1-ARTEMIS™ T cells -iv middle dose, ET190L1-ARTEMIS™ T cells - iv high dose - CD19+ Lymphoma, B-Cell, CD19+ Leukemia, B-Cell | Early Phase 1 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 18 | 2017-12-06 | 2019-03-29 |
| ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma ET1402L1-ARTEMIS™ T cells -IV, ET1402L1-ARTEMIS™ T cells -intra-hepatic artery, ET1402L1-ARTEMIS™ T cells -Intratumoral Injections - Hepatocellular Carcinoma, Liver Cancer | Early Phase 1 | Completed | First Affiliated Hospital Xi'an Jiaotong University | 12 | 2017-12-06 | 2021-03-29 |
| Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma autologous ET1402L1-CART cells - Hepatocellular Carcinoma, Liver Cancer | Phase 1 | Terminated | Aeon Therapeutics (Shanghai) Co., Ltd. | 3 | 2017-10-06 | 2019-07-01 |
| Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma ET190L1 ARTEMIS™ T cells - Lymphoma, B-Cell | Phase 1 | Completed | Eureka Therapeutics Inc. | 4 | 2017-09-09 | 2021-03-16 |
Carcinoma, Hepatocellular (7) · Liver Neoplasms (7) · Lymphoma, B-Cell (4) · Recurrence (2) · Burkitt Lymphoma (1) · Hepatoblastoma (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, Primary Effusion (1)
China (6) · United States (6) · Taiwan (1)
Pei Wang, PhD (4) · Chang Liu, PhD (1) · David A Rizzieri, MD (1) · Jun Zhu, MD (1) · Mei Zhang, PhD (1) · Pengcheng He, M.D. (1) · Qibin Song, M.D./Ph.D. (1) · Xue Hui, PHD (1)